Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- STCC at DHR Health Institute for Research and Development — Edinburg, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Texas: - Houston Methodist Hospital — Houston, Texas
- Covenant Medical Center-Lakeside — Lubbock, Texas
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Texas: - Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas
- Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in Texas: - Texas Oncology - Austin Midtown /ID# 261208 — Austin, Texas
- Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206 — Dallas, Texas
- MD Anderson Cancer Center /ID# 260984 — Houston, Texas
- Oncology Consultants /ID# 268390 — Houston, Texas
- Joe Arrington Cancer Research /ID# 260382 — Lubbock, Texas
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Texas: - Research Site — Shenandoah, Texas
- Research Site — Tyler, Texas
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Texas: - St. David's South Austin Medical Center — Austin, Texas
- University of Texas Southwestern Medical Center — Fort Worth, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Transplant Institute — San Antonio, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Texas: - Center for Oncology and Blood Disorders ( Site 0153) — Houston, Texas
- Houston Methodist Cancer Center ( Site 0154) — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Texas: - Md Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Texas: - MD Anderson Cancer Center - University of Texas — Houston, Texas
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in Texas: - Center for Oncology and Blood Disorders — Houston, Texas
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Texas: - TxO Austin Midtown — Austin, Texas
- Texas Oncology — Dallas, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Texas: - Renovatio Clinical - El Paso — El Paso, Texas
- Renovatio Clinical — The Woodlands, Texas
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Sites in Texas: - Valley Cancer Associates — Harlingen, Texas
- Houston Methodist Hospital — Houston, Texas
- University of Texas, MD Anderson Cancer Center — Houston, Texas
- Baylor Scott & White Medical Center - Temple — Temple, Texas
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- El Paso Children's Hospital — El Paso, Texas
- Methodist Children's Hospital of South Texas — San Antonio, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Texas: - Texas Oncology - West Texas ( Site 8008) — Amarillo, Texas
- Texas Oncology - Central/South Texas ( Site 8006) — Austin, Texas
- Texas Oncology - Northeast Texas ( Site 8002) — Palestine, Texas
- Texas Oncology - San Antonio ( Site 8009) — San Antonio, Texas
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0145) — Tyler, Texas
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Texas: - Texas Oncology - Central South — Austin, Texas
- Texas Oncology - Dallas Fort Worth — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Transplant Institute — San Antonio, Texas
- Texas Oncology - Tyler — Tyler, Texas
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Texas: - The University of Texas M. D. Anderson Cancer Center — Houston, Texas
- Methodist Healthcare System — San Antonio, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Texas: - The University of Texas Md Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Texas: - South Texas Accelerated Research Therapeutics — San Antonio, Texas